Ossianix Inc is a Philadelphia-based biotechnology company specializing in the targeted delivery of therapeutics to the brain. Their innovative TXP1 Brain Shuttle, based on the deimmunised VNAR antibody scaffold, enhances the delivery of therapeutic payloads across the blood-brain barrier by 30-fold, offering a promising solution for the treatment of central nervous system disorders.
With a focus on brain-specific delivery and optimized receptor binding kinetics, Ossianix aims to improve the efficacy of CNS therapies by providing prolonged brain exposure and slow blood clearance at low doses. Their leadership team, led by CEO Frank S Walsh, is dedicated to advancing the science and exploring new opportunities for delivering therapeutics beyond the blood-brain barrier.
Generated from the website